U.S. Food and Drug Administration (USFDA) has concluded surveillance inspection at API unit of Kopran’s wholly owned subsidiary -- Kopran Research Laboratories. The said API unit located at Mahad in Maharashtra. The inspection was conducted from April 21, 2025 to April 25, 2025. The inspection was concluded without any observations.
Kopran is engaged primarily in pharmaceuticals business. The Company manufactures both Active Pharmaceutical Ingredients and Finished Dosage Forms.